Combination therapy with octreotide and α-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors

American Journal of Gastroenterology

Volumn 94, Issue 5, 1999, Pages 1381-1387

  Frank, Margareta ^a   Klose, Klaus J ^a   Wied, Matthias ^a   Ishaque, Natascha ^a   Schade Brittinger, Carmen ^a   Arnold, Rudolf ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEVER; GASTRINOMA; GASTROINTESTINAL TUMOR; HEADACHE; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; FEMALE; GASTRINOMA; HUMANS; INTERFERON-ALPHA; INTESTINAL NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033135279     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(99)00146-X     Document Type: Article

References (32)

1. Creutzfeldt W. Endocrine tumours of the pancreas. In: Arquilla E, Volks BW, eds. The diabetic pancreas. New York: Plenum, 1985:543-63.
2. Arnold R, Neuhaus C, Benning R, et al. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg 1993;17:511-9.
3. Moertel CG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
4. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
5. Ritzel U, Leonhardt U, Stöckmann F, et al. Treatment of metastasized midgut carcinoids with dacarbazine. Am J Gastroenterol 1995;90:627-31.
6. Allison DJ, Jordan H, Hennessy O. Therapeutic embolization of the hepatic artery: A review of 75 procedures. Lancet 1985;i:595-9.
7. Clouse ME, Perry L, Stuart K, et al. Hepatic arterial chemoembolization for metastatic endocrine tumours. Digestion 1994;35(suppl 3):92-7.
8. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: A prospective phase II study in 24 patients. Cancer 1993:71:2624-30.
9. Saltz L, Trochanowsky G, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993:72:244-8.
10. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;3:430-8.
11. Kvols LK, Buck M, Moertel CG, et al. Treatment of metastatic islet cell carcinoma with a Somatostatin analogue (SMS 201-995). Ann Intern Med 1987; 107:162-8.
12. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet cell tumours. Dig Dis Sei 1989;34(suppl):285-91.
13. Di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-8.
14. Öberg K, Funa K, Aim G. Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with midgut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983;309:129-32.
15. Öberg K, Nordheim I, Lind E, et al. Treatment of malignant carcinoid tumours with human leucocyte interferon: Long-term results. Cancer Treat Res 1986;70:1297-304.
16. Öberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol 1992;3:35-41.
17. Dirix LY, Vermeulen PB, Fierens H, et al. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic tumors. An antiangiogenic effect? Anticancer Drugs 1996;7:175-81.
18. Pisegna JR, Slimak GG, Doppman JL, et al. An evaluation of human recombinant a interferon in patients with metastatic gastrinoma. Gastroenterology 1993;105:1179-83.
19. Joensun H, Kätkä K, Kujari H. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenh.) 1992;126:184-5.
20. Hold R, Frank M, Kajdan U, et al. Kombinierte Behandlung metastasierter endokriner Tumoren des Gastrointestinaltraktes mit Octreotid und Interferon-Alpha. Z Gastroenterol 1994;32: 193-7.
21. Capella C, Heitz PhU, Höfler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Digestion 1994;55(suppl 3):11-23.
22. WHO Handbook for reporting results of cancer treatment. WHO: Geneva, 1979:22-7.
23. Öberg K. Endocrine tumors of the gastrointestinal tract: Systemic treatment. Anti-Cancer Drugs 1994;5:503-19.
24. Janson ET, Öberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 1993;32:225-9.
25. Pagliacci MC, Tognelli R, Grignani F, et al. Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201-995: Effects on cell cycle parameters and apoptotic cell death. Endocrinology 1991;129:2555-62.
26. Redding TW, Schally AV. Inhibition of growth of pancreatic cancers in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 1984;81:248-52.
27. McCumbee W, McCarty K, Lebovitz H. Hormone responsiveness of a transplantable rat chondrosarcoma. Evidence for in vivo hormone dependence. Endocrinology 1980;106:1930-40.
28. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 1994;93:1321-5.
29. Wulbrand U, Wied M, Zöfel P, Göke B, Arnold R, Fehmann HC. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumors. Europ J Clin Invest 1998;28:1039-49.
30. Buscail L, Esteve JP, Saint-Laurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin subtypes sstr2 and sstrS through different mechanisms. PNAS 1995;92:1580-4.
31. Norton JA, Doppmann IL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 1992;215:8-18.
32. Jacobsen MB, Hanssen LE, Kolmannskog F, et al. Interferon-alpha 2b, with or without prior hepatic artery embolization: Clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scan J Gastroenterol 1995; 30:789-96.